Trials / Completed
CompletedNCT06444165
Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis
Study to Assess Lebrikizumab Pen Ease of Use in Patients With Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the ease of use of the lebrikizumab pen. Participants will use a practice pad to simulate administration of a dose. Participants will complete the modified Subcutaneous Administration Assessment Questionnaire (mSQAAQ) following the simulated injection. This study involves one study visit.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lebrikizumab Pen | Injected into a practice pad. |
Timeline
- Start date
- 2024-06-04
- Primary completion
- 2024-06-10
- Completion
- 2024-06-10
- First posted
- 2024-06-05
- Last updated
- 2025-07-29
- Results posted
- 2025-07-29
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06444165. Inclusion in this directory is not an endorsement.